For ongoing education and resources, please visit RSNA’s Online Learning Center.
Content Areas (Codes):
The following Content Areas will be printed on the certificate for this course:
- Genitourinary Radiology
- Magnetic Resonance Imaging
- Obstetric/Gynecologic Radiology
Learning Objectives:
- Explain MRI O-RADS (Ovarian-Adnexal Reporting and Data Systems).
- Review the MRI O-RADS governing concepts.
- Recognize the main terms for O-RADS MRI scores 0 and 1.
- Describe the application of O-RADS MRI scores 0 and 1 to adnexal masses and the associated risk of malignancy.
- Recognize O-RADS MRI score 1 lesions by review of cases.
- Describe the MR terms that characterize adnexal lesions that are almost certainly benign (O-RADS 2).
- Identify those MR imaging features that would upgrade an adnexal lesion to a higher O-RADS category.
- Illustrate MR imaging examples of O-RADS 2 lesion such as endometrioma, cystadenoma, mature cystic teratoma, hydrosalpinx and peritoneal inclusion cyst.
- Apply all useful MR features to characterize indeterminate adnexal masses.
- Describe how to perform DCE MR analysis on solid tissue.
- Identify how lesions should be classified O-RADS 3.
- Summarize which adnexal lesions will be rated O-RADS 3.
- Explain the main terms for O-RADS MR score 3.
- Recognize with the application of O-RADS MR score 3 to adnexal masses.
- Recall O-RADS MR score 3 lesions by review of cases.
This enduring material is estimated to take 1 hour to complete.
Start Date: 5/26/2021
End Date for CME Eligibility/Online Expiration Date: 5/25/2024
This educational activity was originally presented at the RSNA 2020 Annual Meeting and Scientific Assembly.
Faculty:
- Andrea G. Rockall, FRCR, MRCP
- Evan S. Siegelman, MD
- Isabelle Thomassin-Naggara, MD
- Elizabeth A. Sadowski, MD
- Caroline Reinhold, MD, MSc
Disclosure Statements:
The ACCME requires that the RSNA, as an accredited provider of CME, disclose the relevant financial relationships of the planners, faculty, and any other individuals in a position to control content of this activity. If there is a relevant financial relationship that has been disclosed please find it below:
- Matthew S. Davenport, MD: Royalties, Wolters Kluwer NV.
- Alexander R. Guimaraes, MD, PhD: Speakers Bureau, Siemens AG; Consultant, Takeda Pharmaceutical Company Limited, Merck & Co, Inc, Agfa-Gevaert Group, PAREXEL International Corporation.
- Ajay Gupta, MD: Support, Siemens AG, General Electric Company.
- Christopher P. Hess, MD, PhD: Research, Siemens AG; Consultant, General Electric Company.
- Vincent B. Ho, MD, MBA: Research collaboration, General Electric Company.
- Maxine S. Jochelson, MD: Speaker, General Electric Company; Consultant, Bayer AG.
- Jeffrey S. Klein, MD: Editor with royalties, Wolters Kluwer NV.
- Petra J. Lewis, MBBS: Committee Member, CairnSurgical.
- Katherine E. Maturen, MD: Royalties, Reed Elsevier, Wolters Kluwer NV.
- Matthew A. Mauro, MD: Board Member, Boston Scientific Corporation; Investor, Medtronic plc, Bayer AG.
- Christine O. Menias, MD: Royalties, Reed Elsevier.
- Charles E. Ray Jr, MD, PhD: Consultant, Medtronic plc; Editor with royalties, Thieme Medical Publishers, Inc.
- Evis Sala, MD, PhD: Co-founder, Cambridge AI Health; Speakers Bureau, GlaxoSmithKline plc.
- Jorge A. Soto, MD: Royalties, Reed Elsevier.
- Bachir Taouli, MD: Research Grant, Bayer AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals, Inc; Consultant, Alexion Pharmaceuticals, Inc, Bayer AG.
- Ioannis Vlahos, MRCP, FRCR: Director, Grayscale Ltd; Co-owner, Grayscale Ltd.
- Abbey Winant, MD: Spouse, Research Grant, Bristol-Myers Squibb Company, Novartis AG; Spouse, Research Consultant, Tango Therapeutics.
- Judy Yee, MD: Research Grant, EchoPixel, Inc, Koninklijke Philips NV, General Electric Company.
- Margarita L. Zuley, MD: Investigator, Hologic, Inc.
- Bachir Taouli, MD: Research Grant, Bayer AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc; Consultant, Alexion Pharmaceuticals Inc, Bayer AG.
- Andrea G. Rockall, FRCR, MRCP: Speaker, Guerbet SA.
- Evan S. Siegelman, MD: Advisory Board, Spreemo Health; Consultant, BioClinica Inc, ICON plc, inviCRO LLC.
- Isabelle Thomassin-Naggara, MD: Researcher, General Electric Company, Canon Medical Systems Corporation; Research funded, General Electric Company, Canon Medical Systems Corporation, Hologic Inc, Siemens AG, Guerbet SA.
All other individuals in control of content have indicated that there are no relevant financial relationships with any commercial interests to be disclosed.
Accreditation and Designation Statements:
The Radiological Society of North America (RSNA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This enduring material can be applied towards the ABR MOC Part 2 requirement (CME).
To earn CME credit, participants must watch the full-length of the recording and complete the course evaluation.
The RSNA designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price:
Non-member Rate: $50.00
Member Rate: $0.00
Refund / Exchange Policy:
RSNA will not issue any refunds or exchanges for online only versions of educational products or activities purchased online. Please review the entire product or activity description prior to purchase.
RSNA Disclaimer:
The opinions or views expressed in this activity are those of the presenters and do not necessarily reflect the opinions, recommendations or endorsement of the RSNA. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product or device mentioned. Information presented, as well as publications, technologies, products and/or services discussed, are intended to inform the learner about the knowledge, techniques, and experiences of RSNA faculty who are willing to share such information with colleagues. The RSNA disclaims any and all liability for damages to any individual user for all claims which may result from the use of said information, publications, technologies, products and/or services, and events.